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Abstract
Background—The World Health Organization (WHO) aims to reduce mortality from chronic 
diseases including cardiovascular disease (CVD) by 25% by 2025. High blood pressure (BP) is a 
leading CVD risk factor. We sought to compare three strategies for treating BP in China and India: 
a treat-to-target (TTT) strategy emphasizing lowering BP to a target, a benefit-based tailored 
treatment (BTT) strategy emphasizing lowering CVD risk, or a hybrid strategy currently 
recommended by the WHO.
Methods and Results—We developed a microsimulation model of adults aged 30–70 years old 
in China and in India to compare the two treatment approaches across a 10-year policy-planning 
horizon. In the model, a BTT strategy treating adults with a 10-year CVD event risk ≥10% used 
similar financial resources but averted about 5 million more DALYs in both China and India than 
a TTT approach based on current U.S. guidelines. The hybrid strategy in current WHO guidelines 
produced no substantial benefits over TTT. BTT was more cost-effective at $205–$272/ DALY 
averted, which was $142–$182 less per DALY than TTT or hybrid strategies. The comparative 
effectiveness of BTT was robust to uncertainties in CVD risk estimation or to variations in the age 
range analyzed, the BTT treatment threshold, or rates of treatment access, adherence, or 
concurrent statin therapy.
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Conclusions—In model-based analyses, a simple BTT strategy was more effective and cost-
effective than TTT or hybrid strategies in reducing mortality.
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The World Health Organization’s General Assembly has adopted a target of reducing 
chronic disease mortality, including mortality from cardiovascular disease (CVD), by 25% 
by 2025 among adults 30 to 70 years old.1 Achieving such a large reduction in CVD 
mortality will likely require more extensive blood pressure (BP) treatment, as high BP is a 
leading modifiable risk factor for CVD mortality.2 Particularly in rapidly-developing 
countries that face the greatest burden of CVD, a key question is how to maximize CVD 
mortality reduction within limited budgets.
Most international BP treatment guidelines are based on U.S. or European guidelines. U.S. 
guidelines have emphasized a “treat-to-target” (TTT) strategy, in which BP therapy is 
titrated until blood pressures fall below a threshold (i.e., ≤140/90 mmHg).3 Conversely, 
European guidelines have emphasized a “benefit-based, tailored” treatment (BTT) strategy 
in which BP therapy is initiated for patients with high estimated CVD risk (i.e., for 
myocardial infarctions [MI] or strokes).4 Both US and European guidelines acknowledge 
that treating high BP is not to lower BP values per se, but to reduce CVD events. The World 
Health Organization (WHO) has proposed a hybrid approach that recommends treating 
patients with both high CVD risk and high BP levels (Figure 1),5 and has distributed “risk 
charts” to aid clinicians.6
Here, we sought to compare population benefits and cost-effectiveness of BTT, TTT, and 
hybrid strategies, using data from China and India—two countries expected to face the 
greatest burden of CVD deaths over the next decade.7
Methods
Study design
We developed and validated two microsimulation models (one for China, one for India; 
Supplemental Figure 1). Microsimulation models estimate risk among individuals by 
repeatedly sampling from correlated probability distributions of risk factors to capture the 
distribution of risk and treatment benefit among diverse populations. The models simulated 
nationally-representative populations of adults 30–70 years old in each country; each 
individual was characterized by age, sex, location (urban/rural), blood pressure treatment 
access, systolic and diastolic blood pressure, total cholesterol, history of diagnosed diabetes, 
and current tobacco smoking. As detailed in the Supplemental Material, individuals were 
assigned these features using a multivariate sampling algorithm for each country, accounting 
for demography-specific risk factors, their inter-correlations and trends.8 We calculated the 
10-year risk of MI or stroke for each individual before and after BP treatment using the 
WHO risk equations, which overcome ethnic biases in traditional risk equations through 
regional calibration.6,9
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We then applied each of three alternative treatment strategies: (1) a TTT strategy based on 
current U.S. guidelines, targeting BP <150/90 mmHg (or <140/90 mmHg if having diabetes 
or being younger than 60 years old);3 (2) a simple CVD risk-based BTT strategy based on 
current UK guidelines,10 recommending treatment for a 10-year combined risk of MI and 
stroke ≥10% (where the 10% threshold was chosen because it approximately matches the 
budget expenditure for the TTT strategy, for fair comparison); and (3) the hybrid approach 
recommended in current WHO guidelines (Figure 1).5 For each treatment strategy, we 
estimated the reduction in CVD morbidity (in MI and stroke events, and disability-adjusted 
life years, DALYs) and mortality over a 10-year policy-planning horizon. A DALY is a 
standard measure of health, where one DALY refers to the loss of one year of healthy life. 
The number of DALYs lost to a disease are calculated as the sum of the years of life lost due 
to premature mortality, plus the sum of years of life lived with disability due to the 
disease.11 To produce fair comparisons, the same proportion of the population is assumed to 
have access to treatment, and the same proportion is assumed to adhere to treatment, in our 
simulations of the TTT, BTT, and hybrid strategies. In sensitivity analyses, we explored 
variations in treatment strategies, CVD risk estimation, treatment access, adherence, and 
concomitant statin treatment.5
Data sources
Input parameters to the model are summarized in Table 1.11–23 Three types of input data 
were incorporated into the models: demographic, population risk factor, and treatment effect 
data. Population-level demographic data for the simulations (age, sex, and urban/rural 
location) were obtained from the United Nations (Supplemental Tables 1 and 2).24 
Population CVD risk factor distributions and their inter-correlations were obtained from the 
WHO Study on Global Aging and Adult Health (SAGE)12 and associated country-specific 
data sources such as the China Health and Nutrition Survey25 (Supplemental Tables 3–13). 
Estimates of the BP reduction achieved through pharmacologic therapy were obtained 
through a comprehensive meta-analysis of BP reduction by medication class, assessed from 
randomized trials (ranging from 7.9 to 9.9 mmHg of systolic BP reduction from standard 
doses of each drug, Table 1);13 a PubMed database search using the terms “systematic 
review” and “blood pressure treatment” found no more recent estimates that would alter 
these estimates.
We applied the effect of BP medication to the subset of the population having access to 
treatment according to the most recent WHO survey (ranging from 65% to 84% access 
among subpopulation cohorts, Table 1)12. We also applied the treatment benefit to the 
subset of the population who typically adhere to BP treatment, which was estimated by 
conducting a PubMed search using the terms “adherence” and “blood pressure treatment”, 
revealing three relevant estimates (averaging ~50% adherence, Table 1).14–16 For those 
treated and adhering, we applied the relative risk reduction from BP reduction estimated in 
three meta-analyses and one cost-effectiveness analysis including meta-regression of 
randomized trials quantifying blood pressure treatment effectiveness by age (ranging from 
relative risks of 0.79 to 0.89 across age groups for a 5 mmHg reduction in systolic BP, Table 
1); through a PubMed database search using the terms “systematic review” and “blood 
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pressure treatment”, no more recent estimates were found that would alter these estimates 
(Table 1).17–20
Treatment approaches
Therapy was prescribed per the algorithms depicted in Figure 1, based on the systolic and 
diastolic averages of two clinically-observed blood pressure measurements, simulated by 
applying a coefficient of variation of 0.09 per measurement to each individual’s untreated 
systolic and diastolic blood pressure to reflect measurement error and biological 
variation.26,27 Choice and dose of drug therapy followed WHO guidelines (see 
Supplemental Material).5 We accounted for the lower blood pressure reduction achieved 
from the third or fourth medication (16% lower) added to the first or second medication in a 
series,28,29 and variation in treatment response (3%).30 As shown in Figure 1, the BTT 
algorithm included the recommended strategy of having a minimum safe level of systolic 
blood pressure below which therapy should not be prescribed regardless of the risk 
calculation (clinically-observed systolic BP <120 mmHg), to avoid possibly increased 
mortality below this level.31
In each year of the simulation, individuals potentially experienced CVD events (MI or 
stroke) based on their calculated risk estimates from the WHO risk equations, which make 
use of the estimated relative risk of CVD events from systolic and diastolic blood pressure, 
total cholesterol, history of diagnosed diabetes, current tobacco smoking, and a prior history 
of MI or stroke (risk factors chosen because of data availability in developing countries; 
Supplemental Table 14). Individuals survived or died based on their demographic-specific 
case fatality rate, capturing local treatment infrastructure and quality (Supplemental Table 
12), and were additionally subject to non-CVD mortality using a competing risks algorithm 
(Supplemental Table 13).32 The microsimulation used discrete-time annual probabilities of 
CVD events and incorporated annually-updated continuous risk factors adjusted for age-
related and secular trends, as detailed in the Supplemental Material. To check the convergent 
validity of the model prior to conducting simulations, we ensured that our projected 
estimates of demographic size were within 5% absolute error of the United Nations 
estimates,24 and that projected estimates of CVD mortality had <5% absolute error from the 
most recent projections by age, sex, and location from the Global Burden of Disease Project 
(Supplemental Figure 2).33
Cost-effectiveness analysis
Because data on non-medical costs (i.e., lost work hours) were unavailable, we used a 
medical perspective for cost-effectiveness analysis, including costs of pharmaceuticals and 
medical service delivery for patients and other payers (Table 1). The costs include screening 
and monitoring at the frequencies observed among patients receiving BP drugs in each 
country, including laboratory costs, personnel costs, overhead expenses, and costs of MI and 
stroke in the year of the event as well as in subsequent years (e.g., rehabilitation).11,22 For 
the BTT and hybrid strategies, we included costs of both cholesterol and diabetes testing for 
those patients who have not yet received such testing (costs shown in Table 1); for the TTT 
strategy, only persons who do not meet treatment criteria for therapy based on age or blood 
pressure alone also incurred costs of diabetes testing. Drug costs included standard doses for 
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generic (off patent) drugs at doses recommended in the WHO essential medicines list (Table 
1).21,34
Disability weights for MI and stroke were obtained from the Global Burden of Disease 
Project35 (Supplemental Tables 14–16). We also included the disutility of receiving 
pharmacotherapy (0.001 per pill per year),36 and an additional probabilistic disutility (0.01 
per person per year) for patients who incur significant side-effects conditional on age, drug 
and dosage (Table 1).13 All costs were expressed in 2015 US Dollars; cost-effectiveness 
ratios compared to the counterfactual of no treatment were calculated after discounting both 
costs and DALYs at a 3% annual rate and compared to the threshold for cost-effectiveness 
of three-times the gross national index per person ($7,380 in China and $1,610 in India) per 
DALY averted.11,37 Consistent with WHO guidelines, we estimated DALYs and costs that 
would accumulate over the life-course of each person alive or born during the period 2016–
2025.11
Alternative treatment strategies and sensitivity analyses
In further analyses, we varied the risk threshold for treatment in the BTT strategy to 15%, or 
to 5% among adults <60 years old; lowered the threshold for BP therapy down to a systolic 
BP of 120mmHg for all persons under the TTT strategy, given results of the Systolic Blood 
Pressure Intervention Trial (SPRINT);38 simulated a 5% rise in access or adherence to 
therapy; modified the BTT strategy to incorporate a “safety valve” of treating everyone with 
systolic BP>150mmHg; increased the upper age for analysis to 85 years; and simulated 
concurrent statin therapy prescribed per WHO guidelines.5,23
In probabilistic sensitivity analyses, we repeated all simulations 10,000 times while 
simultaneously sampling from normal distributions estimated from the means and standard 
deviations of all input parameters, including the CVD risk estimation coefficients, to 
estimate means and standard deviations around all results. The number of iterations was 
chosen as 10,000 as this level of repeated sampling generated stable standard deviation 
estimates to within rounding error. The models were implemented in R (version 3.1.2, R 
Foundation for Statistical Computing, Vienna).
Results
At current treatment access levels, the TTT strategy (Table 2) would recommend treatment 
for 9.0% of 30 to 70 year olds in China (64.4 million people, 95% CI: 63.0–65.9) and 11.0% 
in India (54.9 million people, 95% CI: 53.9–55.9). 81.9% of those recommended for 
treatment in China and 71.4% of those recommended for treatment in India would receive 1 
to 2 medications, with a mean of 1.8 medications per person treated in China and 2.2 in 
India. At 50% medication adherence, 1.1 million MI and stroke events would be averted in 
China (95% CI: 1.0–1.2 million) and 0.8 million in India (95% CI: 0.7–0.9 million), saving 
8.2 million DALYs in China (95% CI: 7.5–8.9) and 6.5 million in India (95% CI: 6.1–6.9). 
While CVD risk was higher in India than in China, fewer events were prevented in India 
given lower treatment access. The costs of TTT would be $3.6 billion in China for a cost-
effectiveness ratio of $435.9 per DALY averted (95% CI: $390.4–$480.8), and $2.6 billion 
in India for a cost-effectiveness ratio of $399.2 per DALY (95% CI: $352.2–445.7). The 
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TTT strategy would avert 391.8 thousand deaths in China (a 4.0% reduction, 95% CI: 3.7–
4.4%) and 325.0 thousand deaths in India (a 3.3% reduction, 95% CI: 3.2–3.6%).
By contrast, the BTT strategy (Table 2) would recommend treatment to fewer people, 5.4% 
of 30 to 70 year old adults in China (38.7 million, 95% CI: 27.2–50.1, 25.7 million fewer 
than TTT) and 6.6% in India (32.9 million, 95% CI: 21.0–44.9, 22.0 million fewer than 
TTT). Among those treated, however, a greater number of medications would be prescribed 
per person; on average, 2.8 medications in China (1.0 more than under TTT), and 3.0 in 
India (0.8 more than under TTT). The BTT strategy would avert more CVD events and 
deaths: 0.8 million more MIs and strokes prevented in China (95% CI: 0.5–1.1) and 0.8 
million more in India (95% CI: 0.5–1.0) than with TTT, and 298 thousand more deaths in 
China (a 7.0% reduction, 95% CI: 5.5–8.4%) and 317 thousand more deaths in India (a 6.4% 
reduction, 95% CI: 4.9–8.0%). The treatment costs of BTT would be $3.7 billion in China 
for a cost-effectiveness ratio $281.0 per DALY averted in China (95% CI: $246.1–317.9), 
and $2.4 billion in India for a ratio of $213.6 per DALY averted (95% CI: $187.3–242.5). 
The hybrid strategy would avert similar numbers of events and DALYs to the TTT strategy, 
at a similar cost, but reduce the number of people on treatment by between one-third and 
one-half (Table 2). Supplemental Figure 3 provides breaks down the three treatment 
algorithms to detail which subpopulations are differentially treated by them in each country.
Because many people would be treated similarly under different strategies, it is informative 
to examine effectiveness and efficiency for those people treated differently by the three 
approaches. We estimated the cost-effectiveness of treatment among patients who would be 
treated most intensively by BTT and the cost-effectiveness of treatment among those who 
would be most intensively by TTT. The population who would be treated most intensively 
by one approach refers to the group prescribed more antihypertensive medications under that 
approach than under the alternative treatment approach. We identified this population in the 
analysis by tracking the number of medications prescribed to each simulated individual 
under both of the alternative treatment strategies. As shown in Table 3, the cost-
effectiveness for those who would be treated most intensively by BTT was much better in 
both countries—at $271.7/DALY, versus $438.2 for those who would be treated most 
intensively by TTT in China, and $192.9/DALY for BTT in India, versus $404.4/DALY for 
TTT. In China, despite almost 28 million fewer people being treated most intensively by 
BTT than by TTT (36.6M vs. 62.3M, respectively), the group most intensively treated by 
BTT would have over 65% more total DALYs averted (12.4M vs. 7.4M). Similarly, in 
India, 22 million fewer people would be treated most intensively by BTT than by TTT 
(28.8M vs. 50.8M), yet the group most intensively treated by BTT would have roughly 
twice as many total DALYs averted (10.0M vs. 5.1M). Those most intensively treated by 
BTT would also use pharmacotherapy more efficiently than the TTT strategy (~22 more 
DALYs per 1000 person-years of pharmacotherapy in China, and ~25 more DALYs per 
1000 person-years in India; Table 3). Those treated most intensively by the hybrid strategy 
would have lower total DALYs saved and cost-effectiveness than the BTT group. 
Supplemental Figure 4 illustrates incremental cost-effectiveness plots of BTT versus the two 
other treatment strategies.
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Detailed subgroup analyses (Supplemental Table 17) revealed that TTT strategy would more 
intensively treated younger people and people with CVD event risks of less than 5% over 10 
years in both China and India. The hybrid strategy would also be more likely than the other 
strategies to focus therapy in people with diabetes. Supplemental Table 18 provides 
characteristics of persons averted from a CVD event across strategies, while Supplemental 
Table 19 provides examples of patients who would be treated differently under each 
strategy.
Alternative treatment strategies and sensitivity analyses
Lowering the risk threshold for BTT treatment from 10% to 5% for persons <60 years old 
would increase the total DALYs averted from 13.2 to 19.4 million in China and from 11.4 to 
12.9 million in India, and the total number of CVD deaths averted from 684.6 thousand to 
1.05 million in China and 634.4 thousand to 788 thousand in India, but worsen the cost-
effectiveness ratio to $406/DALY in China and $278 in India—still better than TTT or 
hybrid strategies (Supplemental Table 20).
Lowering the target for TTT strategy to a systolic blood pressure of 120mmHg or less for all 
persons would increase DALYs averted by 3- to 4-fold in proportion to the larger population 
treated, but at a worse cost-effectiveness ratio (to $542/DALY averted in China, 95% CI: 
$453–626; and $490/DALY averted in India, 95% CI: $405–573) (Supplemental Table 21). 
The same budget and cost-effectiveness ratio would be achieved by lowering the BTT 
threshold to 3.1% in China and 2.4% in India (Supplemental Table 21). Over and above the 
BTT strategy of treating <60 year olds for a risk of at least 5% and ≥60 years old for a risk 
of at least 10%, the incremental gains of treating to a target systolic blood pressure of 
120mmHg would have a cost-effectiveness of $2,400 per DALY averted in China and 
$1,300 per DALY averted in India.
Conversely, raising the BTT treatment initiation threshold to 15% for all adults would 
reduce the benefits of BTT substantially, and also worsen cost-effectiveness ratios as 
compared to the 10% threshold scenario, but the cost-effectiveness ratios were nevertheless 
still be better than the TTT or hybrid strategies (Supplemental Table 22).
Expectedly, improving treatment access and adherence would substantially improve each 
treatment strategy’s absolute benefits. A 5 percentage point increase in treatment access 
would increase the number of deaths averted by 1–9% in China and 12–24% in India 
compared to the baseline estimates, while not significantly impacting the relative benefits or 
cost-effectiveness among strategies (Supplemental Table 23). A 5 percentage point increase 
in adherence would increase the number of deaths averted by between 8% and 28% in either 
country, without significantly impacting the relative benefits or cost-effectiveness among 
strategies (Supplemental Table 24).
Including a “safety valve” in the BTT strategy by treating everyone with systolic 
BP>150mmHg would increase the BTT strategy’s comparative effectiveness, averting ~25% 
more deaths than in the baseline assessment, but required treating 53% of people more 
intensively (Supplemental Table 25).
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Similarly, expanding the age range for analysis to 30 to 85 years old would increase the 
comparative effectiveness of BTT given the higher risk among older adults, reducing 
numbers of CVD deaths by two (India) to five (China) times the baseline assessment when 
accounting for the large population of older adults without significantly worse cost-
effectiveness (Supplemental Table 26). This assumes the benefit of treatment and of a life-
year remains consistent as people age.
Including access to statins (Supplemental Table 27) would reduce the benefits of all three 
hypertension treatment strategies by only 1–4% from the baseline assessment; some CVD 
deaths previously averted by hypertensive therapy were instead averted by the statin therapy, 
and total CVD deaths averted increased by ~21%.
In addition to our pre-specified sensitivity analyses, we performed a post-hoc examination to 
find the level of adherence to BTT that would maintain its comparative advantage over TTT 
and hybrid strategies. If TTT and hybrid strategies maintained 50% adherence, the BTT 
strategy would still be superior in terms of overall DALYs, mortality and cost-effectiveness 
if adherence to BTT were as low as 26% in China and 21% in India.
Discussion
We found that a simple BTT strategy was always more effective than currently 
recommended TTT strategies in reducing CVD events and mortality in both China and 
India, even when accounting for uncertainties in CVD risk estimation, BP levels, other risk 
factors, treatment access and adherence, and concurrent statin therapy. BTT’s relative 
advantage was achieved by treating high-risk, high-benefit individuals more intensively. 
Further, the total DALYs saved by BTT can be greatly improved, without a substantial loss 
in cost-effectiveness, by lowering the treatment initiation threshold in those <60 years old 
from a 10% to a 5% 10-year CVD risk. We estimate that this strategy on its own could 
achieve over one third of the WHO’s CVD mortality target. BTT’s comparative benefits 
require maintaining adherence to a greater pill burden, but adherence would need to be much 
worse to fully negate its greater benefits. Surprisingly, the hybrid strategy in current WHO 
recommendations did not succeed in combining the relative advantages of TTT and BTT, 
but minimally improved upon the TTT approach. The hybrid strategy concentrated therapy 
in population subgroups such as people with diabetes, but also treated such individuals only 
at higher levels of BP, reducing the overall population benefits of BP therapy.
As with any model-based analysis, our results are limited by assumptions and input data. 
First, our analysis used WHO risk equations, which are the basis for global 
recommendations and are regionally calibrated. Some alternative risk scores do not require 
laboratory data,39 but require sparsely-available dietary and physical activity data. Second, 
our sensitivity analyses found substantial improvements in total deaths averted if those age 
70 to 85 are also treated with BTT, but older adults often require more nuanced clinical 
judgment than can be easily modeled. Our analysis also focused on the two outcomes of MI 
and stroke, which reflect over 90% of BP-associated outcomes,2 and have parallel 
relationships to BP as other outcomes such as renal disease.40–42 Hence, our analysis does 
not reflect all-cause benefits of BP treatment, but rather addresses the question of relative 
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benefits among the treatment strategies. Finally, we were only able to account for medical 
costs of treatment and not larger societal costs (such as lost work) from CVD, which could 
lead to conservative estimates BP therapeutic benefits.
Despite these needs for future research, our study revealed that a simple BTT strategy may 
greatly increase population health benefits and improve the cost-effectiveness of BP 
treatment in the two middle-income countries facing the greatest total burden of CVD – 
China and India. Achieving the Sustainable Development Goal of reducing chronic disease 
globally would be better advanced through a BTT strategy than alternative TTT and hybrid 
strategies currently suggested in common guidelines.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank the National Institute of Nutrition and Food Safety, China Center for Disease Control and Prevention, 
Carolina Population Center (R24 HD-050924), the University of North Carolina at Chapel Hill, the U.S. National 
Institutes of Health (R01 HD-30880, R01 DK-056350, R24 HD-050924, and R01 HD-38700), the Fogarty 
International Center at the NIH, and the China-Japan Friendship Hospital, Ministry of Health for the China Health 
and Nutrition Survey (CHNS) data collection and analysis files that were used in this study. We also thank the U.S. 
National Institute on Aging Division of Behavioral and Social Research (R01 AG-034479) and the World Health 
Organization's Department of Health Statistics and Information Systems for the Study on Global Aging and Adult 
Health (SAGE) data collection and analysis files that were used in this study.
Funding Sources: This work was supported by the U.S. National Institutes of Health (SB, grant nos. K08 
HL-121056 and DP2 MD-010478; RH, JS, grant no. P60 DK-20572), the Veterans Affairs Health Services 
Research and Development Service (JS, Career Development Award 13-021), the Rosenkranz Prize for Healthcare 
Research in Developing Countries (SB), the International Development Research Center of Canada (SB), the NIHR 
Research Professorship award (CM), and the Wellcome Trust Capacity Strengthening Strategic Award (CM). The 
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the 
manuscript.
References
1. World Health Organization. Geneva: WHO; 2015. Towards a monitoring framework with targets 
and indicators for the health goals of the post-2015 Sustainable Development Goals. 
2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, AlMazroa MA, Amann M, 
Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, 
Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, 
Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, 
Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, 
Charlson F, Chen H, Chen JS, Cheng AT-A, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, 
Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, 
Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, 
Ferrari A, Finucane MM, Flaxman S, Fowkes FGR, Freedman G, Freeman MK, Gakidou E, Ghosh 
S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, 
Hoek HW, Hogan A, Hosgood HD, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn 
GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang Y-H, 
Khatibzadeh S. A comparative risk assessment of burden of disease and injury attributable to 67 risk 
factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global 
Burden of Disease Study 2010. Lancet. 2012; 380:2224–2260. [PubMed: 23245609] 
Basu et al. Page 9













3. James PA, Oparil S, Carter BL. 2014 evidence-based guideline for the management of high blood 
pressure in adults: Report from the panel members appointed to the eighth joint national committee 
(jnc 8). JAMA. 2014; 311:507–520. [PubMed: 24352797] 
4. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De 
Backer G, Dominiczak A, et al. 2013 ESH/ESC Guidelines for the management of arterial 
hypertension The Task Force for the management of arterial hypertension of the European Society 
of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 
34:2159–2219. [PubMed: 23771844] 
5. World Health Organization. Geneva: WHO; 2013. Package of Essential Noncommunicable (PEN) 
Disease Interventions for Primary Health Care in Low-Resource Settings. 
6. Mendis S, Lindholm LH, Mancia G, Whitworth J, Alderman M, Lim S, Heagerty T. World Health 
Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: 
assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and 
middle-income countries. J Hypertens. 2007; 25:1578–1582. [PubMed: 17620952] 
7. World Health Organization. Geneva: WHO; 2015. Projections of mortality and causes of death, 
2015 and 2030 [Internet]. Available from: http://www.who.int/healthinfo/global_burden_disease/
projections/en/ [cited 2015 Jun 15]
8. Hofert M, Mächler M. Nested Archimedean copulas meet R: The nacopula package. J Stat Softw. 
2011; 39:1–20. [PubMed: 21572908] 
9. Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, Rodgers A. Prevention of 
cardiovascular disease in high-risk individuals in low-income and middle-income countries: health 
effects and costs. Lancet. 2007; 370:2054–2062. [PubMed: 18063025] 
10. Rabar S, Harker M, O’Flynn N, Wierzbicki AS. Lipid modification and cardiovascular risk 
assessment for the primary and secondary prevention of cardiovascular disease: summary of 
updated NICE guidance. BMJ. 2014; 349:g4356. [PubMed: 25035388] 
11. World Health Organization. Geneva: WHO; 2010. Choosing interventions that are cost effective 
(WHO-CHOICE). 
12. Basu S, Millett C. Social epidemiology of hypertension in middle-income countries determinants 
of prevalence, diagnosis, treatment, and control in the WHO SAGE study. Hypertension. 2013; 
62:18–26. [PubMed: 23670299] 
13. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood 
pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003; 326:1427. [PubMed: 
12829555] 
14. Newby LK, LaPointe NMA, Chen AY, Kramer JM, Hammill BG, DeLong ER, Muhlbaier LH, 
Califf RM. Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in 
Coronary Artery Disease. Circulation. 2006; 113:203–212. [PubMed: 16401776] 
15. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, 
Avezum A, et al. Use of secondary prevention drugs for cardiovascular disease in the community 
in high-income, middle-income, and low-income countries (the PURE Study): a prospective 
epidemiological survey. Lancet. 2011; 378:1231–1243. [PubMed: 21872920] 
16. Thomas Dennis NM. Medication adherence and associated barriers in hypertension management in 
India. CVD Prev Control. 2011; 6:9–13.
17. Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Population strategies to 
decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. 
Ann Intern Med. 2010; 152:481–487. W170–W173. [PubMed: 20194225] 
18. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-
specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data 
for one million adults in 61 prospective studies. Lancet. 2002; 360:1903–1913. [PubMed: 
12493255] 
19. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of 
cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from 
prospective epidemiological studies. BMJ. 2009; 338:b1665. [PubMed: 19454737] 
Basu et al. Page 10













20. The Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering 
treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014; 
384:591–598. [PubMed: 25131978] 
21. Management Sciences for Health. International drug price indicator guide [Internet]. Cambridge, 
MA: Management Sciences for Health; 2014. Available from: http://www.msh.org/sites/msh.org/
files/international-drug-price-indicator-guide.pdf [cited 2015 Jan 28]
22. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug 
regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006; 368:679–686. 
[PubMed: 16920473] 
23. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering 
treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of 
statins. Lancet. 2005; 366:1267–1278. [PubMed: 16214597] 
24. United Nations. World Population Prospects: The 2012 Revision. Geneva: UN; 2013. 
25. Popkin BM, Du S, Zhai F, Zhang B. Cohort Profile: The China Health and Nutrition Survey—
monitoring and understanding socio-economic and health change in China, 1989–2011. Int J 
Epidemiol. 2010; 39:1435–1440. [PubMed: 19887509] 
26. National Clinical Guideline Centre. Hypertension: The clinical management of primary 
hypertension in adults, Clinical Guideline 127. London: Naitonal Institute for Health and Clinical 
Excellence; 2011. 
27. Powers BJ, Oddone EZ, Bosworth HB. Measuring blood pressure for decision making and quality 
reporting. Ann Intern Med. 2011; 155:565.
28. Timbie JW, Hayward RA, Vijan S. Variation in the net benefit of aggressive cardiovascular risk 
factor control across the US population of patients with diabetes mellitus. Arch Intern Med. 2010; 
170:1037–1044. [PubMed: 20585069] 
29. Wu J, Kraja AT, Oberman A, Lewis CE, Ellison RC, Arnett DK, Heiss G, Lalouel J-M, Turner ST, 
Hunt SC, et al. A summary of the effects of antihypertensive medications on measured blood 
pressure. Am J Hypertens. 2005; 18:935–942. [PubMed: 16053990] 
30. Bell KJ, Hayen A, Macaskill P, Craig JC, Neal BC, Irwig L. Mixed models showed no need for 
initial response monitoring after starting antihypertensive therapy. J Clin Epidemiol. 2009; 
62:650–659. [PubMed: 19108988] 
31. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP. J-Shaped Relationship between Blood 
Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of 
Individual-Patient Data. Ann Intern Med. 2002; 136:438–448. [PubMed: 11900496] 
32. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis 
of failure times in the presence of competing risks. Biometrics. 1978:541–554. [PubMed: 373811] 
33. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal 
R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 
1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013; 
380:2095–2128. [PubMed: 23245604] 
34. World Health Organization. 19th. Geneva: WHO; 2015. WHO Model List of Essential Medicines. 
35. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana 
M, Kosen S, et al. Common values in assessing health outcomes from disease and injury: disability 
weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2013; 
380:2129–2143. [PubMed: 23245605] 
36. Sussman J, Vijan S, Hayward R. Using benefit-based tailored treatment to improve the use of 
antihypertensive medications. Circulation. 2013; 128:2309–2317. Epub 2013 Nov 4. [PubMed: 
24190955] 
37. World Bank. World Development Indicators 2013 [Internet]. Washington D.C.: World Bank 
Publications; 2014. Available from: https://books.google.com/books?
hl=en&lr=&id=YLXzAI_oVmcC&oi=fnd&pg=PR5&dq=world+bank+world+development
+indicators&ots=dbxEP9Q7Jw&sig=K4O-INdwoBG_ZhMQA7FlX1ebrgo [cited 2015 Jan 28]
38. Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, 
Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman 
WC, Cheung AK, Ambrosius WT. SPRINT Research Group. A Randomized Trial of Intensive 
Basu et al. Page 11













versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373:2103–2116. [PubMed: 
26551272] 
39. Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, Bo J, Lou Q, Lu F, Liu T, Yu L, Zhang S, 
Mony P, Swaminathan S, Mohan V, Gupta R, Kumar R, Vijayakumar K, Lear S, Anand S, 
Wielgosz A, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Yusoff K, Ismail N, Iqbal R, 
Rahman O, Rosengren A, Yusufali A, Kelishadi R, Kruger A, Puoane T, Szuba A, Chifamba J, 
Oguz A, McQueen M, McKee M, Dagenais G. PURE Investigators. Cardiovascular risk and 
events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014; 371:818–827. 
[PubMed: 25162888] 
40. Echouffo-Tcheugui JB, Kengne AP. Risk models to predict chronic kidney disease and its 
progression: a systematic review. 2012 Available from: http://dx.plos.org/10.1371/journal.pmed.
1001344. 
41. Kannel WB, D’Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for 
estimating risk of heart failure. Arch Intern Med. 1999; 159:1197–1204. [PubMed: 10371227] 
42. Murabito JM, D’Agostino RB, Silbershatz H, Wilson PW. Intermittent claudication a risk profile 
from the Framingham heart study. Circulation. 1997; 96:44–49. [PubMed: 9236415] 
Basu et al. Page 12














In May 2012, the World Health Organization’s (WHO) General Assembly adopted a 
target of reducing cardiovascular disease (CVD) mortality by 25% by 2025, setting the 
template for the global “Sustainable Development Goals”. Achieving such a large 
reduction in CVD mortality will likely require more extensive blood pressure (BP) 
treatment. Particularly in rapidly-developing countries, a key question is how to achieve 
the greatest CVD mortality reduction within limited budgets. Here, we sought to compare 
the population benefits and cost-effectiveness of three alternative proposed strategies to 
treat high BP, using data from China and India on treatment access, BP levels, and other 
risk factors for CVD. Our research, which uses a modeling strategy, found that a simple 
treatment approach using calculations of CVD risk to inform treatment decisions was 
more effective and cost-effective than the common strategy of using BP levels to decide 
treatment. The risk-based approach recommends treatment for patients with a 10-year 
combined risk of myocardial infarction and stroke of at least 10%. We also found that the 
current WHO guidelines were worse than the simple risk-based approach; these 
guidelines recommend treating individuals with high CVD risk (≥30% risk over 10 years) 
to a BP of <130/80 mmHg, and individuals with lower risk (20–30% over 10 years) to 
BP <140/90 mmHg. Even with poor treatment adherence, the risk-based approach to BP 
treatment could on its own succeed in achieving between one-quarter and one-third of the 
CVD mortality goal set by the WHO.
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Treat-to-target (TTT, left), benefit-based tailored treatment (BTT, middle), and hybrid 
(right) alternatives. The hybrid strategy is from the World Health Organization (WHO) 
guidelines for hypertension treatment.5 10-year risks in calculated via the WHO risk 
equations.6 CVD: cardiovascular disease; BP: blood pressure; SBP: systolic blood pressure. 
All blood pressure treatment targets are in units of mmHg.
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Table 1
Input parameters for the model. 95% confidence intervals are in parentheses.
Parameter China data India data Source(s)
Population with 
access to blood 
pressure treatment (%)
Urban 84%, rural 81% Urban 74%, rural 65% World Health Organization12
Systolic blood 
pressure reduction 
from standard doses of 
each drug (mmHg)*
Thiazide: 8.8 (8.3–9.4);
Angiotensin converting enzyme inhibitors: 8.5 (7.9–9.0);
Calcium channel blockers: 8.8 (8.3–9.2);
Beta-blockers: 9.2 (8.6–9.9)
Meta-analysis of randomized trials13
Diastolic blood 
pressure reduction 
from standard doses of 
each drug (mmHg)*
Thiazide: 4.4 (4.0–4.8);
Angiotensin converting enzyme inhibitors: 4.7 (4.4–5.0);
Calcium channel blockers: 5.9 (5.6–6.2);
Beta-blockers: 6.7 (6.2–7.1)
Meta-analysis of randomized trials13
Population prescribed 
blood pressure 
treatment who adhere 
to treatment (%)
50% (varied in sensitivity analyses) Observational cohort studies14–16
Relative risk of 
myocardial infarction 





where α = post-treatment minus pre-treatment blood pressure in mmHg 




γ = age in years.
Risk function derived previously17 from 
meta-analysis of randomized trials (R2 = 
0.995 for MI and 0.997 for stroke),18 
validated against independent meta-
analyses (<5% absolute difference)19,20
Relative risk of stroke 





where α = post-treatment minus pre-treatment blood pressure in mmHg 




γ = age in years.
Cost of standard doses 
of each drug (2015 
$US/person/year)*
Thiazide: $1.6 ($1.2–$2.0);
Angiotensin converting enzyme inhibitors: $6.0 ($3.0–$10.3);
Calcium channel blockers: $9.2 ($5.7–$13.7);
Beta-blockers: $3.8 ($2.6–$6.0);
Statin: $19.4 ($8.4–$30.4)
International Drug Price Indicator 
Guide21





Blood pressure therapy annual care: $12 ($8–$16);
MI event: $645 ($363–$927);
Post-MI annual care: $79 ($73–$86);
Stroke event: $883 ($543–$1,223);
Post-stroke annual care: $795 ($548–$1,041);
Diabetes testing (fasting blood glucose): $2 ($1–$3);
Lipid testing (total cholesterol): $1 ($0.5–$2)
Prior cost estimates updated to 2015 
USD11,22
Rate of adverse side-
effects attributable to 
treatment from 
standard doses of each 
drug (%)*
Thiazide: 9.9% (6.6–13.2%);
Angiotensin converting enzyme inhibitors: 3.9% (0.5–8.3%);
Calcium channel blockers: 8.3% (4.3–11.8%);
Beta-blockers: 7.5% (4.0–10.9%)
Meta-analysis of randomized trials13
Relative risk reduction 
when adding statin 
therapy
25% for MI, 19% for stroke Meta-analysis of randomized trials23
*
Standard doses for thiazide is hydrochlorothiazide 25mg, for angiotensin converting enzyme inhibitor is enalapril 5mg, for calcium channel 
blocker is amlodipine 5mg, for beta-blocker is atenolol 50mg, and for statin is simvastatin 20mg.
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Table 3
Relative efficiency of the treat-to-target (TTT), benefit-based tailored treatment (BTT), or hybrid approach 
(based on current World Health Organization guidelines), utilizing current estimates of utilizing current 
estimates of blood pressure levels, blood pressure treatment access, other risk factors, and treatment benefit for 
populations in China and India. Uncertainty intervals are in parentheses.*
Outcome People treated identically












Number of people treated (million n) 2.1 (1.1–3.1) 62.3 (59–65.6) 36.6 (27.8–45.4) 39.4 (36.8–42)
Total DALYs averted (millions) 0.8 (0.5–1.1) 7.4 (7.1–7.7) 12.4 (10.2–14.6) 7.3 (6.9–7.7)
$/DALY among treated 401.4 (222.7–581.7) 438.2 (401.6–475) 271.7 (216.6–328.6) 436.9 (317.9–558.8)
DALYs averted per 1000 patient-years 
of pharmacotherapy
38.1 (37.7–38.5) 11.9 (10.9–12.9) 33.9 (28.2–39.6) 18.5 (17.8–19.2)
India
Number of people treated (million n) 4.1 (3.2–5) 50.8 (47.8–53.8) 28.8 (13.9–43.7) 21.3 (19.6–23)
Total DALYs averted (millions) 1.4 (1.2–1.6) 5.1 (4.8–5.4) 10 (7.6–12.4) 4.8 (4.6–5)
$/DALY among treated 359.1 (293.2–427) 404.4 (294.5–514.4) 192.9 (165.4–223.5) 359.8 (85.3–637.1)
DALYs averted per 1000 patient-years 
of pharmacotherapy
34.1 (31.3–36.9) 10.0 (9.1–10.9) 34.7 (30.2–39.2) 22.5 (21.8–23.2)
*
Uncertainty intervals (in parentheses) were determined by 10,000 iterations with multivariable Monte Carlo sampling from normal distributions 
constructed from the mean and standard deviation of estimated values of all input parameters, including the CVD risk estimation equations. Note: 
The uncertainty range for results of the BTT strategy are greater than for the TTT strategy because it depends on CVD risk estimation, which can 
be impacted by errors in measurement of BP, cholesterol, and knowledge of diabetes diagnosis and prior CVD history; by contrast, the TTT 
treatment decision was only affected by clinical errors in measurement of BP and knowledge of diabetes diagnosis.
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